MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.

ORCHARD PARK, N.Y., Sept. 11  /PRNewswire-FirstCall/ -- MINRAD International, Inc. (AMEX:BUF) today announced that it has notified RxElite Holdings, Inc., a wholly-owned subsidiary of RxElite Inc. (OTC:RXEI) (BULLETIN BOARD: RXEI) , that it is transitioning its relationship with respect to RxElite Holdings, Inc.'s rights to be the exclusive distributor of certain Minrad International Inc.'s anesthetic products in the United States. Minrad has decided to move into a non-exclusive distributor arrangement with RxElite.

"As we discussed in our second quarter conference call on August 14, 2008, we have had ongoing dialogue with the senior management of RxElite to assess and determine how to increase our joint penetration of anesthetic products in the United States market.  We believe this action will maximize the expertise of sales forces of both companies as well as the in-house support capabilities which RxElite has built to launch sevoflurane in the U.S. human anesthetic market," said David DiGiacinto, President and Chief Operating Officer.

Kirk Kamsler, Minrad's Senior Vice President, Commercial Development also commented, "We expect and will work towards ensuring that this ongoing change in selling strategy for our present and future anesthetics in the U.S. market will be transparent to both the distribution customers and end users of this product. Minrad already launched in June a direct selling effort for sevoflurane and isoflurane into the U.S. veterinary market."

   Contact:     David DiGiacinto, President & Chief Operating Officer
                
                Kirk Kamsler, Senior Vice President, Commercial Development
                
                Charles R. Trego, Jr., Executive Vice President & Chief
                Financial Officer
                

                [phone]
                http://www.minrad.com/


  About the Company


MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness.  Additional information can be found at the company's website, http://www.minrad.com/.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. 

DATASOURCE: MINRAD International, Inc.



CONTACT:  David DiGiacinto, President & Chief Operating Officer,

, or Kirk Kamsler, Senior Vice President, Commercial

Development, , or Charles R. Trego, Jr., Executive Vice

President & Chief Financial Officer, , all of MINRAD,

[phone]



Web site:  http://www.minrad.com/ 

Copyright